Drawing for NUFOLIX

USPTO serial 98355035

NUFOLIX

Reviewed by CopyMark Law Group

Status 654
Filing date
Status date
Registration date
—
Examiner
HESIK, APRIL ANNE
Law office
TMO LAW OFFICE 124

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NUFOLIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael Pesochinsky

Michael Pesochinsky Pesochinsky LLC // www.MyBrandMark.com9 Warner WayWayne, NJ 07470United States

Goods and services

ClassDescriptionStatusFirst use
005Dietary supplements; Nutritional supplements; Vitamin and mineral supplementsACTIVEAug 1, 2023

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 21, 2026RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 5, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 10, 2025RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Feb 9, 2025RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Aug 9, 2024GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 9, 2024GNSLLETTER OF SUSPENSION E-MAILED—
Aug 9, 2024CNSLSUSPENSION LETTER WRITTEN—
Aug 8, 2024DOCKASSIGNED TO EXAMINER—
May 5, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 22, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Mar 22, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Mar 22, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 12, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance